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Introduction: Paraneoplastic cerebellar degeneration is a rare non-metastatic manifestation of malignancy. In this
report, to the best of our knowledge we describe for the first time a diagnosis of paraneoplastic cerebellar
degeneration several months prior to the diagnosis of clear carcinoma of the uterus.
Case presentation: A 75-year-old Caucasian woman manifested a rapidly progressive cerebellar syndrome with
nystagmus, past-pointing, dysdiadochokinesis, dysarthria, truncal ataxia and titubation. The paraneoplastic cerebellar
degeneration was associated with anti-Yo and anti-glutamic acid decarboxylase antibodies. 14-3-3 protein was
detected in the cerebrospinal fluid. She was treated with intravenous immunoglobulin prior to laparotomy,
hysterectomy and bilateral salpingoophorectomy. Our patient has survived for three years following diagnosis and
treatment.
Conclusions: To the best of our knowledge this is the first report of an association of clear cell carcinoma of the
uterus and paraneoplastic cerebellar degeneration with both anti-Yo and anti-glutamic acid decarboxylase
antibodies. The findings imply that both antibodies contributed to the fulminating paraneoplastic cerebellar
degeneration observed in our patient, and this was of such severity it resulted in the release of 14-3-3 protein in
the cerebrospinal fluid, a marker of neuronal death.
Keywords: 14-3-3 proteins, anti-Yo/anti-GAD antibodies, clear cell carcinoma of uterus, paraneoplastic cerebellar
degenerationIntroduction
Adult onset progressive cerebellar degenerations repre-
sent complex diagnostic and management challenges for
which genetic and non-genetic causes are recognized.
The non-genetic causes are alcohol and toxins, immune
mediated, vitamin deficiency, leptomeningeal deposition
such as superficial siderosis and chronic infections such
as Whipple’s disease [1,2]. Prion disorders and mutations
in single genes might also cause sporadic ataxia in adults.* Correspondence: research@ndr.org.au
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distribution, and reproduction in any mediumParaneoplastic cerebellar degeneration (PCD) is one of
the most important causes of immune-mediated degen-
erative cerebellar pathology. This is an uncommon con-
dition and can be associated with many different types
of tumor, including small cell cancer of the lung, cancer
of the breast or ovary and lymphoma [3].
Of the gynecological causes, cancers of the ovary are
well recognized. Less appreciated are cancers of the
endometrium. In this report, to the best of our know-
ledge we describe for the first time the association of
clear cell endometrial carcinoma with PCD, anti-Yo, and
anti-glutamic acid decarboxylase (GAD) antibodies with
detectable protein 14-3-3 in the cerebrospinal fluid
(CSF). The diagnosis of PCD led to the diagnosis of
endometrial carcinoma.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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A 75-year-old Caucasian woman reported a three-month
period of general constitutional decline with the onset of
vertiginous symptoms and vomiting one week prior to
attending our emergency department. She had been liv-
ing independently. Her medical history included parox-
ysmal atrial fibrillation treated with amiodarone and
warfarin, hypertension controlled with metoprolol and
irbesartan/hydrochlorothiazide, and right knee osteo-
arthritis. She does not have diabetes mellitus. Her initial
neurological examination results were unremarkable.
She received a putative diagnosis of viral labyrinthitis
and was admitted for intravenous fluid replacement.
Over the next week she experienced troublesome vertigo
but was able to be mobile with use of a Zimmer frame.
Her course was complicated one week after admission
by a fracture of the lateral mass of C2 after falling whilst
mobilizing to the toilet. This required hard-collar
immobilization, which made further investigation prob-
lematic. At this stage she manifested a clinical rapidly
progressive cerebellar syndrome with nystagmus, past-
pointing, dysdiadochokinesis, dysarthria, truncal ataxia
and titubation. Her functional status deteriorated to a
modified Rankin score of 5.
A brain MRI scan revealed no structural abnormal-
ities. Anti-Yo antibodies were found to be present in
serum and CSF, as were anti-GAD antibodies (Table 1).
The CSF showed 0 leukocytes/μL and 50 erythrocytes/
μL, gave negative results on Gram stain and negative
results on culture, her protein level was 0.44 g/L and
glucose level 3.2 mmol/L (concurrent blood glucose
level 5.6 mmol/L), and cytology results were negative
for malignant cells. Oligoclonal bands were notTable 1 Paraneoplastic cerebellar degeneration
Date Fluid Antibodies
Anti-Yo
1 August 2008 Serum 2U (range 0 to 3)
CSF 1U
Serum:CSF ratio = 2:1
5 August 2008 Intravenous Ig 28 g
(0.4 g/kg per day for five days)
1 September 2008 Laparotomy, hysterectomy,
bilateral salpingoophorectomy
9 April 2009 Serum 1U
CSF Undetectable
23 December 2009 Serum 0
24 December 2010 Serum 0
7 November 2011
Anti-Yo antibodies detected by indirect immunofluorescence on a composite block
0 = not detected; 1 =weak positive; 2 =moderate positive; 3 = strong positive). GAD
in U/mL (reference range <1).
CSF, cerebrospinal fluid; GAD, glutamic acid decarboxylase.detected. Her CSF was also positive for protein 14-3-3,
with a single band identified on western blot immuno-
detection. Ca 15–3 and Ca 125 titers were also mildly
elevated in her blood.
A positron emission tomography (PET) scan revealed
a fludeoxyglucose-avid bulky lower uterus evident with
diffuse cerebellar hypo-activity. Pelvic ultrasound
revealed a 4 × 3 cm uterine cyst. A hysterectomy and bi-
lateral salpingoophorectomy confirmed a clear cell car-
cinoma of the endometrium. A diagnosis of stage II
endometrial carcinoma involving and extending into the
stroma of the cervix with vascular invasion and histo-
logical grade 3 was made. She received five cycles of
intravenous immunoglobulin (Ig) prior to surgery. The
original C2 spinal injury and multiple infective compli-
cations including aspiration pneumonia, line sepsis, per-
cutaneous endoscopic gastrostomy (PEG) site infection
and T8/9 discitis made her management difficult. Five
months elapsed from presentation to diagnosis of her
neoplasm. She was too frail for adjuvant chemotherapy.
She was discharged to nursing home care in April 2009,
where she remains to the present day.
She was assessed in December 2009 in her nursing
home where she was found to be bright and alert. She
was dysarthric. She was able to engage in light-hearted
conversation in relation to the performance of Austra-
lian Rules football teams in English and Macedonian.
She was mostly feeding by mouth. The PEG feed was
rarely used. She required a hoist for transfers. She was
able to place both hands against gravity under com-
mand. There was mild tremor of her outstretched hands.
There was impaired finger-to-nose testing that had
improved from the examination of 21 April 2009. SheProteins Findings
Anti-GAD
4.3U/mL (<1) Anti-Yo confirmed
on immunoblot
2.0U/mL 14-3-3





Patient alive; Rankin score 5
of primate cerebellum and cerebrum, and mouse stomach (titers expressed
antibodies (GAD 65) are measured using a radioimmunoassay and expressed
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marked dysmetria in both lower limbs, again much less
than as an in-patient. Deep tendon reflexes were 1+.
There was no clonus. She had nystagmus in lateral gaze
without gaze paresis. There was some limitation in her
upward gaze. Convergence and accommodation reaction
were normal. The cranial nerve examination was other-
wise normal.
When reassessed in August 2011 she remained bed
bound without changes in the neurological examination.
She remains alive to this day, dependent on staff for all
acts of daily living and requiring feeding assistance. Her
weight ranges from 52.8 kg to 61.8 kg.
Discussion
PCD is rare and not commonly associated with endo-
metrial cell carcinoma, particularly clear cell endometrial
carcinoma [4]. PCDs have however been associated with
fallopian tube adenocarcinoma [5]. To the best of our
knowledge this is the first case of clear cell endometrial
carcinoma with anti-Yo antibodies in serum and CSF,
associated with anti-GAD antibodies in serum and CSF;
observations that extend the known associations and
relationships of both of these antibodies and indicates
the importance of an aberrant immune response in
PCD. Our patient’s case is also unique in that 14-3-3
proteins were identified in the CSF, probably related to
neuronal death. Furthermore our patient was given
intravenous immunoglobulin and had surgical treatment
for the endometrial carcinoma. She has remained alive
though disabled for over three years. This therapeutic
outcome supports the notion of a poor therapeutic re-
sponse to intravenous immunoglobulin in patients with
anti-Yo associated PCDs [6] and not a positive treatment
effect observed by others [7,8].
The titers of anti-Yo and anti-GAD antibodies in our
patient decreased in both blood and CSF following treat-
ment, reflecting the reduced immunological response to
the tumor provided by its surgical extirpation and treat-
ment with intravenous Ig (Table 1). Our patient’s case
highlights that the presence of the 14-3-3 protein in
CSF, even though having high sensitivity and specificity
for prion diseases may also be found with PCDs, includ-
ing non-clear cell carcinoma of the uterus [9]. This is an
important practice point in that in a patient with a cere-
bellar syndrome, where there might be considerations of
a prion disease and where 14-3-3 proteins are found, the
physician needs to consider the possibility of an under-
lying cancer.
14-3-3 proteins have previously been observed in a pa-
tient with anti-GAD associated cerebellar ataxia [10].
Furthermore anti-GAD antibodies are not only asso-
ciated with stiff-person syndrome but in about 20% with
cerebellar ataxia [11]. Our patient is distinctive in thatboth the anti-Yo and anti-GAD antibodies can be impli-
cated in the cerebellar degeneration.
The pathophysiology of the cerebellar degeneration is
probably a consequence of a direct cytotoxic effect of
the anti-GAD antibodies on the Purkinje cells [12] and
possibly an apoptotic effect of the anti-Yo antibody after
uptake by cerebellar Purkinje cells [13-15]. The patho-
physiological effects of both antibodies resulted in the
fulminating and devastating cerebellar syndrome in our
patient. The initial cell damage might involve cell-
mediated immunity, as these antibodies recognize intra-
cellular antigens; this mechanism is supported by the
unsuccessful attempts to transfer the disease in animals
by antibodies or immunization.
Conclusions
To the best of our knowledge this is the first report of a
PCD caused by clear cell carcinoma of the uterus with
both anti-Yo and anti-GAD antibodies, in association
with 14-3-3 proteins in CSF. These observations increase
our understanding of the antibodies related to PCD in
gynecological malignancies and is of relevance to neurol-
ogists, gynecologists, general internists, oncologists and
clinical immunologists.
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